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Abstract 
Osteoarthritis (OA) is an age-related joint degenerative disease associated with pain, joint 
deformity and disability. The disease starts with cartilage damage but then progressively 
involves subchondral bone causing an imbalance between osteoclast-driven bone resorption 
and osteoblasts-driven remodeling. Herein we summarize the data for the role of oxidative 
stress and inflammation in OA pathology and discuss how these two processes are integrated 
during OA progression, as well as, their contribution to abnormalities in cartilage/bone 
metabolism and integrity. At the cellular level, oxidative stress and inflammation are 
counteracted by transcription factor nuclear factor-erythroid p45-related factor 2 (Nrf2), and 
we describe the regulation of Nrf2, highlighting its role in OA pathology. The beneficial 
effect of some phytonutrients, including the therapeutic potential of Nrf2 activation, in OA is 
also discussed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 2 of 46
http://www.nyas.org/forthcoming
Annals of the New York Academy of Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
unedited manuscript
3 
 
Introduction 
Osteoarthritis (OA) is one of the most common degenerative arthropathy in the elderly 
population. OA is a time- or age-dependent progressive destruction of joints related to 
articular cartilage damage, synovial lining thickening, subchondral bone alterations, 
osteophytes formation at the joint margin, and is supported by elevated inflammatory and 
catabolic responses, which finally result in a loss of joint architecture and deformity.
1-4
 The 
disease affects mostly individuals over the age of 50 (primary disease), but it can also develop 
after joint insult and trauma in younger individuals (post-traumatic OA). Several lines of 
evidences suggest that aging has an impact on the pathogenesis of primary disease. Some OA 
chondrocytes acquire aging phenotype with increased genomic instability, telomere 
shortening, epigenetic alterations including decreased genomic global methylation and histone 
modifications, dysregulated metabolism, mitochondrial dysfunction and altered intercellular 
networks and cascades.
5-7
 The disease progresses and the age-dependent alterations in cell 
signaling and metabolism occur in chondrocytes but also in bone cells (osteoclasts and 
osteoblasts), causing an imbalance between bone resorption and remodeling and deeper 
abnormalities in subchondral bone and joint structure. Aging causes OA development, 
however it is not a sole risk factor. The disease is multi-factorial with both physiological and 
mechanical processes involved, such as obesity, genetic predisposition, hereditary, metabolic 
or endocrine alternations, trauma, joint overload and mechanical stress, as well as, long-time 
exposure to a low-grade chronic inflammation concomitant with a failure in oxidant-
antioxidant balance.
5-8
 Therefore, some aspects of OA pathology are still a subject of an 
extensive research.
4,9
 
 Inflammation and oxidative stress have been increasingly recognized as being closely 
integrated in OA pathology. Various inflammatory mediators such as cytokines [tumor 
necrosis factor-α (TNF-α), interleukin (IL)-1β, 8, 6, 15, 17, 18, 21, 33],
10
 chemokines, 
prostaglandins (PGEs)
11
 and growth factors [transforming growth factor-α (TGF-α)], 
fibroblast growth factor (FGF) are increased in the joint tissue of OA patients in comparison 
to healthy individuals.
9
 Local inflammatory response along with aging and/or mechanical load 
can contribute to increased oxidative stress with accumulation of reactive oxygen species
12
 
(ROS), superoxide anion, hydrogen peroxide (H2O2), nitric oxide (NO) and peroxynitrite and 
concomitant failure in the expression of antioxidant enzymes and ROS scavenging systems.
13
 
At cellular level, oxidative stress causes mitochondrial DNA (mtDNA) and nuclear DNA 
damage, lipid peroxidation, alterations in cell signaling, transcription and epigenetic changes 
in gene expression. At the level of the joint as a whole organ, oxidative stress causes 
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abnormalities in the cartilage and bone metabolism, exacerbating not only degradation but 
also overall reparative potential of chondrocytes, osteoblasts and their precursors.
13,14
 Thus 
the regulation of redox homeostasis at cellular level can decrease the severity of OA and limit 
the disease progression. 
The Cap'n'Collar basic leucine zipper transcription factor nuclear factor-erythroid 2 
p45-related factor 2 (Nrf2, also called Nfe2l2) is the master regulator of the cellular redox 
homeostasis. Nrf2 regulates the expression of a large network of cytoprotective genes, 
including enzymes involved in the biosynthesis, utilization and regeneration of reduced 
glutathione (GSH), thioredoxin and nicotinamide adenine dinucleotide phosphate (NADPH), 
detoxification enzymes such as glutathione S-transferases (GST), aldo-keto reductases 
(AKR), and NAD(P)H:quinone oxidoreductase 1 (NQO1), heme oxygenase 1 (HO-1), as well 
as proteins involved in the recognition and clearance of damaged proteins and organelles, 
such as proteasomal subunits and autophagy-related proteins.
15-16
 Collectively, the products of 
the Nrf2-target genes function to lower the intracellular levels of ROS, reactive nitrogen 
species (RNS) and electrophiles, thus protecting the cell from the harmful effects these agents. 
In addition, Nrf2 is involved in the regulation of expression of a number of metabolic genes, 
most notably those involved in the pentose phosphate pathway, the biosynthesis of purine 
nucleotides and serine, and enhance fatty acid metabolism and mitochondrial function.
17-21
 
Overall, the Nrf2 regulatory network provides an interface between redox and intermediary 
metabolism.  
Recently, several studies have revealed the essential role of Nrf2 in preventing the 
patho-physiological events in joint diseases.
22
 It has been shown that the appropriate 
expression and fine balance in Nrf2 activity is absolutely necessary for normal 
chondrogenesis and proper regulation of cartilage metabolism.
12,23
 There is growing evidence 
for the involvement of Nrf2 in bone resorption and remodeling indicating a multi-faceted 
effect in sustaining overall bone integrity. Herein, we attempt to summarize the recent 
findings for the essential role of Nrf2 in OA. We also discuss the underlying mechanisms of 
regulation and biochemical crosstalk between Nrf2, ROS signaling and inflammation during 
OA pathogenesis. The beneficial role of phytonutrients to attenuate cartilage/bone 
degradation, inflammation and oxidative stress in OA is highlighted. 
 
Nrf2 function and regulation 
Nrf2 is expressed in most cell/tissue types and comprises seven functional domains, arranged 
as follows from its N- to C- terminus: Neh2, Neh4, Neh5, Neh7, Neh6, Neh1, Neh3 (Figure 
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1). The Neh4 and Neh5 domains form the transactivation domain of the transcription factor 
that recruits CREB-binding protein (CBP). The retinoid X receptor α (RXRα) represses Nrf2 
by binding to its Neh7 domain. Neh1 mediates binding to DNA and to the heterodimeric 
partner of Nrf2, transcription factor of the family of small musculoaponeurotic fibrosarcoma 
(Maf) proteins. Neh3 recruits the chromo-ATPase/helicase DNA-binding protein 6 (CHD6). 
The Neh2 and the Neh6 domains contain specific sequences (degrons) that mediate the 
degradation of Nrf2.
24
 Nrf2 is regulated primarily at the level of protein stability. At 
homeostatic conditions, the levels of Nrf2 are low due to its continuous ubiquitination and 
proteasomal degradation. In response to stress signals, Nrf2 accumulates, translocates to the 
nucleus, and as a heterodimer with a small Maf, initiates transcription of its target genes.
24 
There are three known ubiquitin ligase systems, which have been implicated in the 
degradation of Nrf2 (Figure 2). The major negative regulator of Nrf2 activity is Kelch-like 
ECH-associated protein 1 (Keap1). Keap1 was identified as a result of studies which followed 
on from the finding that deletion of the Neh2 domain of Nrf2 (to which Keap1 binds) resulted 
in its greatly increased activity.
25
 Subsequent research has elucidated the process by which 
Keap1 downregulates the Nrf2 activity. Keap1 forms a homodimer via its BTB domain.
26-28
 
The regions of Keap1 important for interacting with Nrf2 are its Kelch (also known as double 
glycine repeat, DGR) domains and C-terminal regions, and each Keap1 molecule interacts 
with one of two proximal portions of Nrf2, the DLG and ETGE motifs (Figure 1).
29
 Both of 
these motifs lie within the Neh2 domain of Nrf2, separated by an alpha helix, and due to their 
different electrostatic potentials, the ETGE motif has an approximately 100-fold higher 
affinity for Keap1 than the DLG motif.
30
 A “hinge and latch” hypothesis has been proposed 
whereby the low affinity site (latch) serves to position Nrf2 such that its lysine residues are 
optimally oriented for ubiquitination, while the high affinity site (hinge) is primarily 
responsible for keeping Nrf2 bound to Keap1.
31
 Keap1 uses a cyclic mechanism to 
sequentially bind to the ETGE and the DLG motifs of Nrf2.
32
 While bound to both of these 
sites of Keap1, Nrf2 is in a prime position for ubiquitination by Cullin-3 (Cul3)-Rbx1/Roc1 
ubiquitin ligase (i.e., CRL
Keap1
), which is recruited to the complex via interactions with the 
BTB domains of the Keap1 dimer.
28
 Ubiquitinated Nrf2 is extracted from the Keap1-Cul3 E3 
complex by the ATP-dependent segregase p97,
33
 and degraded by the 26S proteasome - this 
regulation maintains the half-life of Nrf2 at 10-20 minutes, and ensures low basal Nrf2 
activity.
29 
Besides acting as the primary inhibitor of Nrf2 activity, Keap1 serves as the 
intracellular sensor for electrophiles and oxidants,
27
 which bring about stabilisation and 
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activation of Nrf2. This is mediated through specific reactive cysteine residues of Keap1, 
some of which have lower pKa values than most cysteine residues due to their surrounding 
basic amino acids, meaning they exist as thiolate anions (S
-
, as opposed to SH) making them 
more reactive with ROS, RNS and electrophiles. Which cysteine residues are modified 
depends on the type of activator,
34
 with C151, C273 and C288 being most commonly 
modified.
35-37
 Small molecule electrophiles and oxidants chemically modify Keap1 cysteine 
residues, which is hypothesized to alter the structure of the complex, preventing 
ubiquitination and subsequent degradation of the transcription factor. This results in Keap1 
becoming saturated with Nrf2 and allowing newly synthesised Nrf2 to accumulate in the 
cytoplasm, translocate to the nucleus and induce expression of its target genes.
32
 
Alternatively, some toxic metals (As
3+
, Cd
2+
, and Cr
6+
) have been found to stabilise Nrf2 by 
dissociating it from Keap1.
38
 Other small molecule Nrf2 activators directly disrupt the Keap1 
: Nrf2 protein : protein interaction.
39,40 
Upon translocation to the nucleus, Nrf2 forms heterodimers with a small Maf protein, 
and this dimerization is necessary for efficient DNA binding.
41
 Nrf2-Maf heterodimers bind 
their target gene promoters at antioxidant response elements (ARE), which comprise the core 
sequence 5′-TGACnnnGC-3’, in which the GC dinucleotide is a critical part.
42
 Both of these 
transcription factors contain a basic leucine zipper (bZIP) motif found within their DNA-
binding domains, with the basic region contributing to DNA binding and the leucine zipper 
facilitating dimerization.
38
 As mentioned above, the Neh4, Neh5 and Neh3 domains of Nrf2 
(Figure 1) are responsible for mediating transactivation of target genes by recruiting a 
number of coactivators, whereas the small Maf has no transactivation domain, and does not 
contribute to this process.
43
 Coactivators recruited include CREB-binding protein (CBP), 
coactivator-associated arginine methyltransferase 1 (CARM1) and protein arginine methyl-
transferase 1 (PRMT1), which appear to synergise with another recruited coactivator, receptor 
associated co-activator 3 (RAC3) to facilitate Nrf2-mediated gene expression.
44
 Other studies 
have unveiled more bZIP binding partners, with which Nrf2 dimerizes, including activating 
transcription factor 4 (ATF4), Fos and Jun.
45
 While these heterodimers have been shown to 
bind to the ARE, it has not yet been made clear the extent to which they participate in 
regulating gene expression. Additionally, Nrf2 transactivation is subjected to negative 
regulation by retinoic X receptor α (RXRα), which binds Nrf2 and sits at the ARE to prevent 
binding of Nrf2-Maf heterodimers.
46
 A recent study has shown that Nrf2 binds to MED16,
47
 a 
tail subunit of Mediator, a highly conserved large conformationally flexible macromolecular 
complex, which is required for RNA polymerase II-driven transcription of all protein-coding 
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genes.
48,49
 Pull-down assays have indicated that the Neh4/Neh5 and the Neh1 domains of 
Nrf2 are involved in this interaction.
47 
In addition to Keap1, Nrf2 is targeted for degradation following glycogen synthase 
kinase 3 β (GSK3β)-mediated phosphorylation (Figure 2).
50,51
 This kinase phosphorylates 
serine residues in the Neh6 domain of Nrf2, leading to the recruitment, through DSGIS and 
DSAPGS motifs (Figure 1), of the dimeric β-transducin repeat-containing protein (β-TrCP), a 
substrate adaptor for the Skp1-Cul1-Rbx1/Roc1 E3 ligase complex (i.e., SCF
β-TrCP
), hence 
resulting in the degradation of the transcription factor. Activation of certain kinase cascades, 
including phosphoinositide 3-kinase (PI3K)/Akt and mitogen-activated protein kinase 
(MAPK) pathways, leads to inhibition of GSK3β, and certain Nrf2 activators such as the 
lignan nordihydroguaiaretic acid (NDGA), have been shown to activate Nrf2 via induction of 
these pathways and GSK3β inhibition.
52
 A third ubiquitin ligase system, the endoplasmic 
reticulum (ER)-bound E3 ligase Hrd1 (also known as synoviolin), has been implicated in the 
degradation of Nrf2 during ER stress (Figure 2).
53
 Acetylation also plays a role in Nrf2 
regulation – the histone acetyl transferases (HAT) p300 and CBP modify lysine residues of 
Nrf2 within its Neh1 domain to promote its DNA-binding capacity at certain target genes.
54 
The activity of Nrf2 can be affected by transcriptional and epigenetic mechanisms. 
Thus, Nrf2 transcription is upregulated by the arylhydrocarbon receptor (AhR) and 
BRCA1,
55,56,57
 whereas it is downregulated in the livers of peroxisome proliferator-activated 
receptor α (PPARα)-null mice following a 24-h period of fasting.
58
 In addition, Nrf2 is 
upregulated in tumor cells with mutant K-Ras
G12D
 or B-Raf
V619E
, and it has been proposed that 
this upregulation is mediated by transcription factors Jun and Myc.
59
 Nrf2 can also activate its 
own transcription due to the presence of an ARE-like sequence (5′-CTGACTCCGCC-3′) in 
its promoter.
60
 The promoter of the murine Nrf2 gene contains five CpG sequences, which 
have been shown to be hypermethylated in a mouse model of prostate cancer, resulting in a 
transcriptional silencing of Nrf2 and lower target gene expression.
61 
Accumulating experimental evidences suggest that micro-RNAs (miRs) also play a 
role in the regulation of Nrf2. In human MCF-7 breast cancer cells, ectopic expression of 
miR-28 leads to a decrease in the mRNA and protein levels of Nrf2.
62
 Overexpression of 
miR-93 has also been shown to reduce the levels of Nrf2 (mRNA and protein) as well as its 
downstream target gene NQO1 in human MCF-10A and T47D breast cancer cells.
63
 
Conversely, the downregulation of miR-93 increased the expression of Nrf2 and its target 
gene heme oxygenase 1, and had a protective effect in a mouse model of stroke.
64
 In human 
SH-SY5Y neuroblastoma cells, ectopic expression of miR-27a, miR-142-5p, miR-144 and 
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miR-153 results in a decrease in the mRNA and protein levels of Nrf2 and the expression of 
NQO1.
65
 Downregulation of miR-27a increased Nrf2 expression and improved cardiac 
function in a mouse model of LPS-mediated sepsis.
66
 Interestingly, in homozygous sickle cell 
disease (HbSS) reticulocytes, increased levels of miR-144 are inversely associated with the 
levels of Nrf2, and correlate with decreased glutathione regeneration and attenuated 
antioxidant capacity in HbSS erythrocytes.
67
 A recent study has shown that miR-144 reverses 
chemoresistance in hepatocellular carcinoma cell lines by targeting the 3'-untranslated region 
(3'-UTR) of Nrf2 and promoting its mRNA degradation.
68
 By a similar mechanism, miR-153 
downregulates Nrf2, whereas tanshinone IIA, a diterpene quinone from Salva miltiorrhiza, 
restores this downregulation, leading to protection of SH-SY5Y cells against 6-
hydroxydopamine-induced toxicity.
69 
 
Pathogenesis of osteoarthritis 
Osteoarthritis is a worldwide problem accounting for 1.1% of global disability-adjusted life 
years
10
 and the fourth leading cause of disability,
22
 accompanied by pain, and depression, with 
social impact on the patients’ families.
4,5,9
 Currently, available therapies are limited in 
efficacy because of the complex pathology and attended side effects.
70
 Most therapies only 
aim to reduce and control OA symptoms and pain, but they fail to provide a cure and thus 
total joint replacement is often required in the most severe cases of OA.
22,10,70 
At the early stage of disease the changes in chondrocyte function and survival lead to 
progressive cartilage disintegration and deterioration. In some patients this process can be 
accompanied and perpetuated by secondary inflammation and synovitis.
71
 Cartilage 
degeneration accelerates catabolic processes and bone removal by osteoclasts (bone 
resorption) resulting in bone cysts and sclerotic bone formation. Cartilage and bone loss 
trigger compensatory repair by osteoblasts with excessive anabolic processes of neocartilage 
formation at the joint margins and joint edges (osteophytes), periarticular fibrosis and 
calcified bone formation in advanced disease. The repair at specific site of the joints is a 
consequence also of generalized alteration in the intrinsic capacity of subchonrial bone to 
repair the cartilage and in the cross-talk between immune and bone cells.
8
  
Despite that OA can be diagnosed quickly by imaging techniques, the disease 
progresses slowly within years before the first symptoms and a risk score for the individual's 
susceptibility to OA can be predicted based on analysis of genetics, age and environmental 
factors in combination with molecular and imaging biomarkers.
8
 Such prediction can be 
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based on the assumption that the primary disease develops as a continuum. Mutations and 
errors in gene expression of matrix molecules or factors regulating matrix component 
synthesis can render chondrocytes hypertrophic and dysfunctional and can cause 
chondrodysplasia at a relatively early age.
8
 Chondrocytes can acquire this altered phenotype 
progressively especially when they are situated near weight-bearing regions. Over-time (at 
middle-age; with aging) OA susceptibility can increase because of supplementary 
mechanical and structural disorders in the joints associated with reduced physical activity 
and muscle strength, altered bone metabolism, infections, joint injury, inflammation and 
unhealthy diet.
8
 Finally, age-related changes in growth factor signaling required for 
morphogenesis and repair contribute to OA onset in the elderly population.
8
 At middle- and 
late-onset, different cell types can be involved in the pathology – chondrocytes, synovial 
fibroblasts, bone and immune cells, and all of them may potentially show aberrant gene 
expression and a failure in oxidant-antioxidant balance. With respect to secondary disease, 
increased susceptibility to develop OA might be related to altered epigenetic modifications 
of cartilage after injury. Indeed, more than 1000 differentially methylated regions (DMRs) 
have been detected in human knee articular cartilage upon damage.
72
 Additional impact in 
the secondary disease is chronic inflammation often related to dysfunction in immune 
mechanisms and/or immune cell homeostasis.
73 
 
Role of inflammation and oxidative stress in osteoarthritis 
Inflammation and interaction between immune and bone cells in OA 
One unresolved link in primary OA is the contribution of inflammation in disease initiation 
and progression. Several studies have shown a significant association between OA severity 
and the presence of inflammatory synovitis).
71,74
 Besides OA synovial fibroblasts, OA 
chondrocytes show altered expression of inflammatory genes, of genes encoding 
transcription factors or regulatory genes and of genes, associated with the loss of correct cell 
maturation.
75,76
 Indeed, overexpression and overproduction of pro-inflammatory cytokines 
have been clearly shown to be part of OA pathology.
9,10,11
 In chondrocytes, cytokines 
activate PI3K/Akt and NF-kB signalling pathways, up-regulate matrix metalloproteinases 
(MMPs)/aggrecanases expression and increase DNA hydroxymethylation via attenuation of 
ten-eleven translocation 1-3 (TET1-3) enzymes.
77
 OA chondrocytes can also produce 
chemokines, such as IL-8, that drive neutrophil accumulation.
78,79
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Indeed, neutrophils can impact seriously OA pathology. It has been found that blood 
neutrophils from OA patients with active disease respond to in vitro stimulation with elicited 
pro-inflammatory cytokine production and show elevated expression of bone-damage 
accelerating  receptor activator of nuclear factor-κB (RANKL).
80
 Mature neutrophils 
expressing RANKL are found in synovial fluid of mice with OA
81
 and disease improvement 
is associated with inhibition of RANKL expression on neutrophils.
82
 Neutrophils actually 
endow a destructive phenotype in blood that is further extended and sustained in arthritic 
synovium.
83
 In turn, they can drive osteoclast differentiation and maturation from precursor 
cells directly via RANKL-RANK pathway or they can manipulate chondrocyte and 
osteoblast functions indirectly via ROS, cytokines and growth factors secretion. Neutrophils 
can cooperate with NK cells to build the local immune response and can induce general 
changes in NK homing and activation via secreted chemokines
73
 that in turn can fail to 
support normal cartilage and bone repair. It is still unclear if some of the abnormalities in 
advanced OA are related to age-dependent dysfunction in immune cells and ROS signaling 
as well as with a shift in the expression of myeloid lineage genes and changes in the 
composition and quality of the tissue-restricted pools of immune cells.
84
 
 
Role of oxidative stress in OA pathology 
During the past decades, tremendous progress has been made in understanding the role of 
oxidative stress in health and diseases. ROS including H2O2, O2•
−
, and •OH are byproducts 
of normal cellular metabolism. ROS are generated during electron transport chain reactions 
delivering electrons to molecular oxygen in the mitochondria. The process is restricted by 
the redox enzyme p66
Shc
, which is translocated in the mitochondria in response to 
exogenous signals delivered by growth factor deprivation, oxidative stress or UV 
irradiation.
85,86
 Generated H2O2 can diffuse across the outer mitochondrial membrane to the 
cytosol where it can modulate the activity of “ROS sensors” such as the thiol functional 
group of the amino acid cysteine in proteins. Subsequently, the oxidative cysteine 
modifications can modulate cytosolic protein functions, akin to phosphorylation and can 
increase mitochondrial permeability and biogenesis.
86
 H2O2 also downregulates the activity 
of the forkhead transcription factor FoxO3, implicated in the expression of mitochondrial 
antioxidant enzymes, that in turn increase both hydrogen peroxide scavenging and oxidative 
stress resistance.
87
  
ROS generation in mitochondria can often change during aging resulting in persistent 
endogenous ROS production at small amounts contributing to aging-related mitochondrial 
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dysfunction, swelling and apoptosis together with alterations in chondrocyte senescence and 
apoptosis. This pathway is considered to play the minor role in the total ROS accumulation 
but it has the key implication in aging-dependent alterations in OA.
14,22
 
The significant amounts of ROS are generated via non-mitochondrial pathway, i.e. 
NADPH oxidase (NOX) or dual oxidase (DUOX) assembles found at the discrete regions at 
the plasma or endosomal membranes. In phagocytic cells, the active oxidase contains the 
catalytic subunit (gp91phox), the regulatory subunits (p22phox, p47phox, p40phox, 
p67phox) and the small signaling G protein kinase. Later it was discovered that non-
phagocytic cells from various tissues can express one of the seven homologues of the 
gp91phox: NOX 1-5 and DUOX 1-2, all containing conserved domain structure of six 
transmembrane α-helices and an electron transfer center with two haems forming the 
electron transport channel through the membrane.
88
 The C-terminal domain of the multi-
component oxidase binds to the electron-donating pyridine nucleotide NADPH and to the 
various cofactors such as flavin adenine dinucleotide (FAD) or Ca
2+
 in order to generate 
superoxide. In a subsequent reaction, two molecules of superoxide can generate H2O2. 
Similarly to the mitochondrial pathway, H2O2 can induce reversible modifications of 
cysteine containing proteins like tyrosine phosphatases adjacent to receptors for growth 
factors, cytokines and chemokines or like phosphatidylinositol-3,4,5-trisphosphate 3-
phosphatase (PTEN) responsible for the hydrolysis of the bioactive lipid 
phosphatidylinositol 3,4,5-trisphosphate. In such a way, the NOX enzymes can regulate the 
downstream signaling for cell activation, differentiation, proliferation and apoptosis in 
healthy cells. H2O2 can diffuse in the cytosol but NOX complexes are present at the lipid 
rafts
89
 and assemble at focal adhesion regions,
90
 restricting H2O2 to specific cellular micro-
domains and preventing aberrant signaling.  
Another system for ROS generation involves the constitutively expressed enzyme 
xanthine oxidoreductase (XOR). XOR is highly expressed in intestine and liver and also in 
synovium, lung, kidney and brain. The XOR activity is versatile and tuneable at multiple-
levels.
91
 At genetic level the expression of the enzyme can be regulated by nutritional factors, 
oxygen tension, steroid hormones, phorbol esters, regenerative and hyperplastic stimulus, 
cytokines implicated in inflammation (like IFN-γ and TNF-α)
91
. The enzyme can exist in two 
forms - dehydrogenase and xanthine oxidase (XO) as it undergoes irreversible partial 
proteolytic cleavage or reversible post-translational modifications via thiol oxidation.
92,93
 
During the latter convertible alteration, XOR enzyme is modified from dehydrogenase via 
intermediate form to reversible XO.
91
 The conversion of XOR to XO has been observed in a 
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variety of hypoxic and ischaemic conditions in the tissues including synovium and has been 
related with vascular response to oxidative stress and the regulation of pro-inflammatory and 
pro-thrombotic activities of endothelial cells.
91
 The mechanisms include the metabolic 
alterations and the activation of transcriptional factors, including hypoxia-inducible factor-1 
(HIF-1) and protein kinases.
94
 XOR can catalyze the oxidation of hypoxanthine to xanthine, 
can act as a NADH oxidase (the XO form) to catalyze the subsequent oxidation of purines to 
urate and can catalyze the reduction of nitrates and nitrites, being the rate-limiting enzyme in 
purine catabolism as well as being the constant source of ROS, NO and peroxynitrite.
92,93,95,96
 
XOR level in synovial fluid is elevated in OA patients but in a lesser extent in comparison to 
that in patients with rheumatoid arthritis,
97
 and its amount in synovium correlates with the 
severity of joint injury
97-99
 and inflammasome activation driving OA progression.
100
 More 
than 50% of synovial XOR exists in oxidase form and is expressed in synovial tissue upon 
injury.
97,101
 Increased XO activity is associated also with altered adhesion and accumulation 
of leukocytes in microvasculature and elevated ROS and cytokine production by infiltrating 
and locally activated monocytes and neutrophils.
91
   
Several scavenging systems are available in the cells to detoxify ROS: the enzymes 
superoxide dismutases (SOD), catalase, glutathione peroxidase and glutathione reductase.
102
 
SOD1 is a dimeric cytosolic enzyme that binds copper and zinc (Cu/ZN-SOD), whereas 
SOD2 is a mitochondrial homo-tetramer that binds one manganese ion per subunit (Mn-
SOD). Both enzymes convert superoxide to H2O2 and diatomic oxygen. Catalase is a 
tetrameric protein that converts H2O2 to H2O and gaseous O2. In the cytosol glutathione 
peroxidase/glutathione reductase system maintains the reducing environment in the cells. 
When ROS production escapes the antioxidant systems and mechanisms, the cells are 
exposed to oxidative stress and become sensitive to the activation of apoptotic pathways. 
ROS-mediated damage by oxidative stress can be often reversed by repair, replacement, 
degradation or sequestration of the damaged macromolecules, but in some cases the stress 
can be sustained driving mitochondrial and cell death or mutagenesis.
85,86
 The biological 
effects of ROS in all cell types are due to hyperperoxidation, protein carbonylation, direct 
DNA damage, telomere shortening, epigenetic alterations of gene expression and failure in 
DNA repair, changes in receptor and metabolic pathways and autophagy. However, the 
sources of ROS may differ in various cell types and may be dependent on cell type 
functional and metabolic state.  
Abnormal ROS signaling has been described in OA synovial tissue, fibroblasts 
chondrocytes, osteoblasts and osteoclasts, concomitant with spatiotemporal progression of 
Page 12 of 46
http://www.nyas.org/forthcoming
Annals of the New York Academy of Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
unedited manuscript
13 
 
injury from the articular surface to the subchondral bone. ROS generation can be influenced 
by underlying chronic inflammation involving immune cells or by generalized alterations in 
cell-driven repair affecting nuclear reprogramming (Figure 3). Indeed low level of ROS is 
important for normal osteoclastogenesis and osteoblastogenesis to sustain bone integrity, 
whereas high level of ROS may contribute to mitochondrial dysfunction and alterations in 
signaling pathways and gene expression that in turn cause chondrocyte apoptosis and 
senescence, subsequent cartilage degradation, and changes in subchondral bone and 
processes of bone resorption and remodeling. 
 
ROS signaling and nuclear programing 
Recently several studies have drawn a clear link between ROS signaling and nuclear cell 
programming. At physiological levels, ROS can alter nuclear reprogramming of somatic 
cells to pluripotency, restricting cellular and genomic damage during self-renewal or 
preventing inappropriate differentiation of pluripotent cells.
103,104
 The mechanism can 
involve the inhibition of Nox family members, which increases genomic stability and/or the 
activation of innate immunity as a positive feedback cycle of ROS generation.
105
 During 
early reprogramming, antioxidant enzymes are upregulated, Nrf2 expression gradually 
increased in coordination with changes in mitochondrial biogenesis and bioenergetic 
functions.
105
 Supplementary mechanism to affect pluripotency is the regulation of H2O2 
production from superoxide and consequent cysteine oxidation of transcriptional factors or 
epigenetic modifiers by H2O2.
106
 Such findings encourage the researchers to use inducible 
pluripotent stem cells (or adult stem cells) for the treatment of degenerative diseases like 
OA, where an alteration of the cartilage and bone tissue reparative capacity has been 
described. Experiments with undifferentiated human mesenchymal stem cells (hMSCs) have 
shown higher levels of glycolytic enzymes, increased rate of glycolysis for energy supply 
and of ROS signaling.
107
 During the differentiation of hMSCs to osteoblast cells however, 
the ability to produce ROS is lost because of increased ROS scavenging and upregulation of 
antioxidant enzymes, and of transition from glycolysis to oxidative phosphorylation.
108
 The 
underlying mechanism involves initial increase of Nrf2, NF-κB and AP-1 activity, and 
induction of hypoxia-inducible factor expression (HIF-α).
108
 
 
ROS signaling and OA synovial fibroblasts 
Increased expression and protein content of the pro-oxidant enzymes Nox2 and XO have 
been shown in synovial tissue of patients with knee OA.
109
 The level of the enzymes 
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correlates with local expression of prolidase, an imidodipeptidase with a role in the 
recycling of collagen.
110
 Prolidase is regulated at the post-transcriptional level by integrin-
dependent signaling delivered from stimulatory (i.e., thrombin) or inhibitory (i.e., echistatin) 
β1-integrin ligands or by nitric oxide donors.
110
 Indeed in serum of patients with knee OA, 
increased oxidant (measured by ROS, total peroxide and lipid hydroperoxide levels) and 
decreased antioxidant state (measured by antioxidant capacity, thiol level and catalase 
enzyme activity) are related with elevated serum prolidase activity
111
 and elevated 
inflammasome activity in synovium, indicating a link between ROS signaling, inflammation 
and cartilage collagen metabolism.
109
 
OA synovial fibroblasts show higher production of chemokines, IL-1β, TNF-α and 
increased expression of thrombin.
112,113
 Thrombin contributes to fibrin deposition, 
angiogenesis, proliferation and proinflammatory processes in OA synovium involving the 
intensive cleavage of osteopontin
114
 and the activation of HO-1.
113
 The latter enzyme is a 
stress-inducible rate-limiting enzyme in heme degradation responsible for cytoprotection 
against oxidative injury and is upregulated via the activation of PKCδ, c-Src, and Nrf2.
113
 
Thrombin secreted by OA fibroblasts can also alter the metabolism of cartilage 
chondrocytes via HO-1. The mechanism involves an increased production of insulin-like 
growth factor-1, a reduction of insulin-like growth factor binding protein-3, a decreased 
activation of ERK 1/2, an elevated activity of MMPs.
115
 Alterations in OA synovial 
fibroblasts have been also related to their increased sensitivity to local NO donors which 
directly contribute to elevated ROS production and oxidative stress.
116
 Oxidative stress in 
OA fibroblasts trigger MAPKs phosphorylation, TAK1-mediated NF-kB activation and 
Cox-2/PGE2 expression, both reversible by antioxidants such as N-acetylcysteine and 
hyaluronic acid.
116
 The production of local inflammatory mediators and ROS in OA 
synovium sustains the proliferative ability of OA fibroblasts and alters the regulatory 
mechanisms of MMPs, cytokine and growth factors expression. For example IL-1β as well 
as ROS can induce the expression of particular miRNAs, which control NF-kB activation, 
translocation and acetylation. On the other hand, miRNA expression can be controlled by 
histone deacetylases (HDACs), enzymes sensitive to ROS signaling. Recent studies have 
shown that HDAC inhibitors can directly suppress gene expression of iNOS and MMPs in 
OA fibroblasts. Indirect effects of their administration include the alteration of NF-κB 
activity and translocation, changes in phosphorylation of p38 and ERK, and control of miR-
146a expression.
117,118
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ROS signaling and OA chondrocytes 
Articular human normal cartilage is composed of a hydrated extensive extracellular matrix 
(ECM) in which a small number of cells (2-3% of the total tissue volume) named 
chondrocytes are embedded. These cells are the only cell type in the normal mature articular 
cartilage, which are metabolically very active and normally do not divide after adolescence. 
They maintain homeostasis and balance of matrix synthesis and degradation, as well as repair 
damaged cartilage tissue in OA.
10,119
 Cartilage catabolism comprises secretion of proteases, 
suppression of matrix synthesis and inhibition of chondrocyte proliferation, while the 
anabolism is associated with secretion of antagonistic cytokines, synthesis of protease 
inhibitors, production of extracellular matrix and cell replication. Early changes in the 
articular surface include fragmentation, fibrillation and gradual thinning of cartilage and loss 
of viscosity of the synovial fluid with alteration in the biochemical composition.
10,119
 
Articular chondrocytes from OA patients are deteriorated and have irregularly 
orientated mitochondria. Indeed chondrocytes near the fibrillated regions show swollen 
mitochondria with disoriented cristae and nearby glycogen vacuoles, indicative of altered 
cell metabolism.
120
 In culture, OA chondrocytes show increased mitochondrial mass [as a 
result of increased citrate synthase (CS) activity] but reduced mitochondrial respiratory 
activity and changes in mitochondrial membrane potential in comparison to normal 
chondrocytes.
14,121
 The collapse of the mitochondrial membrane potential results in 
mitochondrial swelling, disruption of outer mitochondrial membrane and release of pro-
apoptotic factors, such as cytochrome c, apoptosis-inducing factor and pro-caspases.
14
 A 
proteomic study has demonstrated that enzymes involved in glycolysis significantly 
decrease in OA chondrocytes
119
 along with a deficiency in mitochondrial SOD, catalase and 
glutathione scavenging systems; overproduction of ROS, NO, det imental peroxynitrite and 
reduction of the ATP pool.
119
 Several genomic, lipidomic
122
 and high-resolution mass 
spectrometry analysis
123
 have identified enrichment in pathways related to lipid 
(eicosanoids) metabolism and oxidative stress in OA chondrocytes. It is assumed that 
excessive cartilage load can trigger abnormalities in ROS release, mitochondrial functions 
and energy/metabolic state in some predisposed individuals and in some areas of cartilage. 
In those individuals altered ROS signaling can be sustained by aging, itself, resulting in the 
senescence secretory phenotype of chondrocytes. This phenotype includes the upregulation 
of the expression of matrix metalloproteinases (MMPs) and aggrecanases, cytokines and 
growth factors and the integration with the PI3K-Akt, p38, ERK and NF-kB signaling 
linking cell receptor with metabolic pathways.
124
 Consequently, more chondrocytes at the 
Page 15 of 46
http://www.nyas.org/forthcoming
Annals of the New York Academy of Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
unedited manuscript
16 
 
superficial zone acquire alterations in total DNA methylation profile,
125
 in histone 
acetylation of anabolic genes (like SOX9 gene) and in particular miRNA leading to a failure 
in regulation of transcription and stability of antioxidant, inflammatory and metabolic 
genes.
126
 The persistent ROS generation in combination with altered ROS scavenging in 
cartilage cause a progressive mitochondrial damage in most of the chondrocytes with 
changes in oxidative phosphorylation, redox signaling, miRNAs-regulated mitochondrial 
biogenesis
127
 and expression of mitochondrial ROS antagonist chaperones.
119
 As a result, 
chondrocyte apoptosis at superficial cartilage areas increases, and chondrocytes at deeper 
zone become hypertrophic disrupting normal endochondral ossification and matrix repair. 
Hypertrophic chondrocytes usually have metabolic and proliferation defects that can be 
overcome by the antioxidant treatment with N-acetylcysteine
128
 or the administration of 17β-
estradiol.
129
 They also show alteration in HO-1. The enzyme is responsible for the 
degradation of heme to carbon monoxide (CO), free iron and biliverdin-IX. In mammals, 
biliverdin-IX is further converted to bilirubin-IX, and endogenous radical scavenger with 
recognized anti-inflammatory properties. On the other hand free iron is rapidly sequestered 
into the iron-storage protein ferritin, leading to additional antioxidant and antiapoptotic 
effects. CO has also several biological functions, with antiapoptotic and anti-inflammatory 
properties.
113
 
Recently it has been shown that the accumulation of ROS in chondrocytes can lead to 
mitochondrial DNA (mtDNA) mutations. Researchers have even identified the specific 
mitochondrial DNA haplogroups J and T that have been associated with variations in the 
prevalence and progression of cartilage loss in some European populations.
130-133
 In 
particular, J haplotype has been linked to lower serum levels of markers of collagen type-II 
degradation and of matrix metalloproteinases and higher ATP levels in the Spanish 
population, while T haplotype correlates with lower disease risk in a small UK cohort.
131-133
 
 
ROS signaling and OA osteoclasts and osteoblasts 
The osteoclasts drive the processes of bone resorption and bone matrix loss. The osteoclasts 
are differentiated from bone marrow monocyte precursors. The process is dependent on NF-
kB signaling driven by RANKL-RANK or is regulated by IL-17, GM-CSF and/or IFN-γ. 
Osteoblasts, stem cells, stromal cells, neutrophils, NK cells and even migrated in the bone 
marrow CD4
+
 T cells can drive osteoclastogenesis via direct contact. It has been shown that 
RANKL-RANK system stimulates ROS generation in osteoclasts.
134
 The administration of 
the antioxidants N-acetylcysteine and glutathione attenuates RANKL-mediated Akt and 
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ERK activation and NF-kB signaling (via inhibition of IKK activity and IkBa 
phosphorylation) as well as it reduces bone resorbing activity and regulates osteoclasts 
apoptosis.
135
 RANKL-mediated ROS production and osteoclast differentiation is abrogated 
and blocked when bone marrow precursors are depleted of Nox1 by siRNA or by expression 
of a dominant-negative mutant of Rac1.
134
 The same group has shown that the role of ROS 
signaling for osteoclast differentiation is dependent on activation of JNK The osteoblasts 
drive the opposite process of bone resorption, bone remodeling and repair. In OA the 
balance between activation of osteoclasts and osteoblasts leads to abnormal remodeling and 
formation of osteophytes. Similarly to osteoclastsand p38 and transcription factor NF-
ATc1.
134
 RANKL can attenuate Nox2 mRNA expression but it can upregulate Nox1 and 
Nox3 transcription during the differentiation of macrophage linage to osteoclasts.
136
 Indeed 
siRNA targeting of p67(phox) or p22(phox) in macrophage linage downregulates ROS 
generation, suppresses RANKL-induced osteoclastogenesis, inhibits the expression of 
osteoclast marker genes (TRAP, cathepsin K, Atp6i, ClC-7, and NF-ATc1).
136
 
Osteoblasts drive the opposite process of bone resorption, bone remodeling and repair. 
In OA the balance between activation of osteoclasts and osteoblast leads to abnormal 
remodeling and formation of osteophytes. Similarly, to osteoclasts, osteoblasts are sensitive to 
ROS signaling during their differentiation from mesenchymal cells. Osteoblastogenesis 
involves Runx2-dependent and -independent mechanisms of gene expression and is 
dependent on growth factor signaling pathways triggered by bone morphogeneic proteins 
(BMPs), transforming factor (TGF)-β and Wnt cascade. Recently it has been shown that 
BMP-2 induces a rapid generation of ROS and activation of NADPH oxidase and that Nox4 
activation is a key factor for osteoblast differentiation in response to BMP-2.
137
 In 
differentiated OA osteoblasts however oxidative stress can have several impacts on their 
functions. The administration of the antioxidant N-acetylcysteine elevates osteocalcin and 
type I collagen synthesis and decreases alkaline phosphatase activity in OA osteoblasts. The 
mechanisms involve activation of p38 and JNK1/2, but not ERK1/2 kinases, induction of 
ATF-2/CREB activation, inhibition of NF-κB, and activation of COX-2 promoter activity via 
CRE site. Consequently, the antioxidant increases COX-2 and PGE2 levels but decreases 
TNF-α induced IL-6 production.
138 
 
Nrf2 and OA pathogenesis 
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As a master regulator of the cellular redox homeostasis, Nrf2 induction may play a key role in 
OA pathophysiology. Nrf2 is responsible for the activation of glutathione-S-transferase, 
NQO1,
12
 and glutathione peroxidase activities
139
 thus attenuating early joint pain.
140
 Nrf2 is a 
promoter of HO-1 expression,
102,141
 prevents 4-hydroxynonenal (HNE)-induced mitochondrial 
damage,
3
 and its deficiency in mice leads to more severe OA development.
141
 HO-1 and γ-
glutamylcysteine ligase (γ-GCLC) act synergistically as phase 2 antioxidants and were found 
in higher levels due to Nrf2 activation.
142
 In addition, Nrf2 is involved in the regulation of 
ROS production by mitochondria and NADPH oxidase.
143
 
  Studies in Nrf2-deficient mice have shown that they are highly susceptible to 
chemical-induced toxicity and oxidative burden, as a result of dysregulation/loss of 
expression of detoxification, xenobiotic metabolism and redox genes.
144,145
 However other 
genes including those involved in protein transport, ubiquitination, phosphorylation, cell 
cycle, growth and apoptosis have been identified to be also Nrf2-dependant.
146
 By using 
ChIP-Seq and microarray analyses, 645 basal and 654 inducible direct targets of Nrf2 were 
identified and confirmed to be related with stress response and cell proliferation in mouse 
embryonic fibroblasts.
147
 In humans, polymorphisms in the ARE sequences, to which Nrf2 
binds, have been reported.
148
 Concerning inflammatory responses, a recent review discussed 
the role of Nrf2 in the regulation of the expression of HO-1 during hematopoiesis, 
development and activation of lymphoid cells and macrophages as well the interaction 
between Nrf2 and NF-kB and the mechanism of Nrf2-regulated NLP3 inflammasomal 
activity.
149
 
Abnormal ROS signaling in OA synovial fibroblasts by cytokines, thrombin or stress 
is associated with increased Nrf2 activity. Oxidative stress in cartilage may trigger activation 
of Nox4 and mitochondrial dysfunction. However, both factors may be counteracted by 
increased Nrf2 activation in fibroblasts.
150
 Nrf2 regulates thrombin-induced production of 
HO-1 in synovial fibroblasts and consequently, inhibition of the Nrf2-dependent signaling 
pathway by Nrf2 siRNA, diminishes HO-1 expression. Thrombin increases the Nrf2 
phosphorylation and binding to the ARE element of HO-1 gene promoter. Nrf2 activity is 
attenuated by inhibitors of PAR1/PAR3, PKCδ, and c-Src pathways indicating that all of 
them are involved in thrombin-induced Nrf2 activation in human synovial fibroblasts.
113
 
Nrf2 activation antagonizes cytokine-induced NF-kB signaling by limiting IkBα 
degradation, suggesting that a failure in this reciprocal interaction may also occur in OA 
synovial fibroblasts as they over-produce inflammatory cytokines.
149
 However, the specific 
environment in OA cartilage may contribute to a different role of Nrf2 in OA fibroblasts in 
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comparison to that in fibroblasts from other tissues. For example skin fibroblasts from 
patients with systemic sclerosis show decreased Nrf2 activity along with elevated 
inflammatory gene expression and fibrosis. In skin fibroblasts, the Nrf2 silencing 
constitutively elevates collagen synthesis, spontaneous myofibroblast differentiation, and 
enhances TGF-ß responses
151
 showing that Nrf2 may be a key cell-intrinsic anti-fibrotic 
factor sustaining extracellular matrix homeostasis in systemic sclerosis.
151
 In another study 
using human periodontal ligament fibroblasts, it has been demonstrated that H2O2-mediated 
oxidative stress decreases the osteogenic differentiation of fibroblasts via interference with 
Wnt/β-catenin signaling and Nrf2 expression at protein and mRNA levels.
152
 
 Nrf2 plays a major chondroprotective role in the progression of OA and suppresses IL-
1β-induced MMP-1, MMP-3 and MMP-13 expression at both mRNA and protein levels, and 
induces the expression of phase 2 antioxidant enzymes, such as NQO1 and HO-1,
9,11,141
 as 
well as suppresses the PGE2 and NO production and inhibition of the phosphorylation of NF-
ĸB p65 and IĸBa in human OA.
11
 It has been demonstrated that histone deacetylase inhibitors 
(HDACi),
141
 physical activity,
142
 phytochemicals, such as protandim, 6-gingerol,
3
 ascorbic 
acid,
153
 sulforaphane,
154
 curcumin,
155
 carotenoids,
156
 as well as broccoli
157
 and sesame oil are 
protective in models of OA by activation of Nrf2.
139
 Downregulation of Nrf2 could result in 
inhibition of chondrogenesis through apoptotic cell death, but on the other hand stable 
overexpression of Nrf2 caused inhibition of chondral differentiation by reduction of the 
characteristic markers, such as type II collagen (Coll II), type X collagen (Coll X) and 
osteopontin. This means that appropriate expression and fine balance in Nrf2 activity is 
absolutely necessary for normal chondrogenesis and proper regulation of OA.
12,23
 Nrf2 can 
also regulate indirectly chondrocyte apoptosis and senescence via the expression of 
glyoxalase I (an enzyme that detoxifies methylglyoxal).
10
 This enzyme regulates the levels of 
the advanced glycation products (AGEs).
10
 The levels of AGE such as urinary pentosidine 
correlate with the degree of cartilage damage and chondrocyte loss.
158,159
 Thus, the 
overexpression of the receptors of AGEs in OA might suppress Nrf2 and glyoxalase I, 
respectively.
10
 
Nrf2 has been reported to play important roles in the regulation of inflammatory 
processes. The induced expression of IL-1β and TNF-α results in higher expression of NO, 
which inhibits chondrocytes cytoskeletal actin polymerization and beta-1 integrin-dependent 
signaling, decreased expression of IL-1β receptor antagonist and TGF-β, suppression of 
chondrocyte collagen and proteoglycan synthesis, activation of MMPs and suppression of 
proliferation, as well as, promotion of apoptosis. NO suppresses energy metabolism and 
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directly induces calcification of articular cartilage. During apoptosis mitochondria sequester 
Ca
2+
 in providing energy to the cells. The excessive Ca
2+
 concentrations lead to the opening of 
the mitochondrial permeability, which depolarizes the mitochondria and leads to 
mitochondrial swelling and apoptosis.
14
 Nrf2 inhibits NF-kB activation and the production of 
inflammatory mediators, such as IL-1β and PGE2, as well as, MMP-1, MMP-3 and MMP-13, 
which are important risk factors that have the ability to inhibit type II collagen synthesis in 
ECM.
11,154
 The mechanisms of this inhibition are just beginning to be understood, and include 
repression of transcription of pro-inflammatory genes.
160
 
Several lines of evidences indicate that Nrf2 is an important factor for osteoclast and 
osteoblast differentiation as well as to sustain normal skeletal and bone metabolism. Nrf2-
deficient mice have lower bone mass and bone strength.
161
 The same authors described that 
the deletion of Nrf2 inhibits the load-driven gene expression of antioxidant enzymes and 
Wnt5a in cultured primary osteoblasts
161
 indicating that Nrf2 regulates the overall bone 
homeostasis. Nrf2 is a key factor in the maintenance of bone microarchitecture as observed 
in an animal model of postmenopausal osteoporosis.
162
 Nrf2 deficiency promotes the 
RANKL-induced activation of p38, c-Jun, ERK, induces c-Fos and NF-kB activation and 
osteoclastogenesis, likely due to dysfunction in the production of antioxidant enzymes and 
glutathione.
163
 The overexpression of Nrf2 enhances the expression of anti-oxidant enzymes, 
inhibits osteoclast differentiation and attenuates lipopolysaccharide-mediated RANKL-
dependent cranial bone destruction in vivo.
164
 The same authors showed that during 
osteoclastogenesis, the precursor cells lose Nrf2, fail to translocate Nrf2 in the nucleus 
because of Keap1 upregulation, and downregulate cytoprotective enzymes (HO-1, γ-
glutamylcysteine synthetase, and glucose-6-phosphate dehydrogenase), elevating ROS 
production.
164
 Consistent with this report is a study demonstrating increased oxidative stress 
in bone marrow-derived cells from ovariectomized Nrf2-deficient mice and a higher 
responsiveness of bone marrow-derived cells to osteoclastogenic stimuli in vitro.
162
 
Knockout mice of BTB and CNC homology 1 (Bach1)—the competitor of Nrf2 in 
transcriptional regulation attenuate RANKL-mediated osteoclastogenesis.
165
 The mechanism 
involves RANKL-dependent nuclear import of Bach1 and Nrf2 nuclear export, which 
attenuates Nrf2-mediated antioxidant enzymes and ROS signaling in osteoclasts. Moreover, 
the induction of Bach1 nuclear export inhibited bone destruction in vivo.
165
 Nrf2 knockdown 
or deletion increases osteoclastic differentiation from bone marrow-derived macrophages via 
upregulation of transcription factor NFATc1.
166
 Interestingly, in this study Nrf2 inhibits 
osteoblast differentiation and mineralization via suppression of Runx2, osteocalcin, and 
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osterix.
166
 The number of osteoblasts in bone is increased in Nrf2-knockout mice in 
comparison to wild-type mice, indicating that both osteoclastogenesis and 
osteoblastogenesis are dependent of Nrf2 or at least require its presence.
166
 When Nrf2-
deficient mice are irradiated, the bone loss and RANKL expression markedly increase, but 
the mineralization of calvarial osteoblasts decreases, suggesting that loss of Nrf2 can 
activate ROS signaling, altering the sensitivity to radiation-induced bone damage. 
Importantly, all of these effects are restored by the antioxidant N-acetylcysteine.
167
 The role 
of Nrf2 in osteoblast-driven bone formation has been demonstrated in a model of fracture 
healing. The underlying mechanism is related to elevated expression of vascular endothelial 
growth factor (VEGF) and diminished production of osteocalcin in Nrf2-deficient mice.
168
 
Together, these studies have shown that Nrf2 plays a key role in regulation of the balance 
between osteoclast-driven bone resorption and osteoblast-driven remodeling (Figure 4).  
However, in Nrf2-deficient mice, altered bone metabolism has not been studied with 
respect to a dysfunctional immunity or/and cytokine production imposing the need for 
further investigations. It has not been yet considered whether Nrf2 has a critical role in 
maintaining hematopoietic stem cell function, including effects on cell quiescence and self-
renewal potential. Nrf2 favors the commitment of both myeloid and lymphoid lineages 
suggesting that Nrf2 imposes a general regulatory role in bone marrow niches.
169
 Thus, Nrf2 
may regulate osteoclastogenesis or osteblastogenesis by stabilization of bone marrow niches 
with progenitors. It has been shown that Nrf2-deficient mice have more severe cartilage 
damage in two models of OA, destabilization of the medial meniscus (DMM) and 
monosodium iodoacetate (MIA) models.
141
 The chondroprotective role of Nrf2 in these 
models was mediated by the use of HDAC inhibitors inhibiting OA-associated proteins 
MMP1, 3, 13 and pro-inflammatory cytokines TNF-α, IL-1β, and IL-6. Because inhibition 
of HDAC fails to improve the disease in Nrf2-deficient mice,
141
 this supports the notion for 
a more general cell dysfunction that is likely mediated by epigenetic mechanisms. 
 
The manipulation of stem cells via Nrf2 
The manipulation of stem cells (from different origin; stem cells or adipose-driven) is a new 
strategy exploiting the key role of Nrf2 in cell differentiation, senescence and apoptosis. It 
has been shown that the generation of osteoblast cells from stem cells can be achieved by 
silencing of Nrf2 and autophagy. In vivo, bone formation is enhanced by injection of Nrf2 
knockdown stem cells.
170
 Moreover, therapy with adipose-driven stem cells can be improved 
Page 21 of 46
http://www.nyas.org/forthcoming
Annals of the New York Academy of Sciences
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
unedited manuscript
22 
 
by promoting endothelial progenitor cell migration and angiogenesis under hypoxia via 
TLR4-mediated NF-kB signaling and antioxidant-driven Nrf2 activation.
171
 
 
Anti-inflammatory drugs in OA therapy 
Currently, there is no enough satisfactory drug for effective OA treatment and hence OA 
cannot be cured totally. Moreover, the existing treatment strategies aim only to control the 
symptom and reduce the pain.
22
 Although there are promising candidates they are limited in 
efficacy and associated with certain toxicity.
70
 The current management of OA includes: first, 
behavioral interventions (patient education, exercise and change in life style); second, simple 
analgesic, such as acetaminophen (paracetamol); third, application of nonsteroidal anti-
inflammatory drugs (e.g., COX-2 inhibitors); fourth, intraarticular injections of 
corticosteroids, hyaluronic acid and glucosamine; and fifth, total joint replacement in the most 
severe cases of OA.
22,70
 Bisphosphonates might have symptomatic and structural benefits for 
patients with OA. Pamidronate disodium was able to prevent completely OA pathology in 
rabbits through osteoprotegerin receptor activator of NF-kB ligand. Aldendronate reduced 
osteophyte formation and articular cartilage degeneration.
9
 HDACi have emerged as potential 
therapeutic strategy of OA treatment. Its effect is linked with the acetylation of Nrf2, which 
enhances its functions in OA.
141
 
 
Effect of plant derived or synthetic antioxidants on Nrf2 expression in 
osteoarthritis 
Plants-derived antioxidants have a great potential to modulate Nrf2 expression. For example, 
curcumin has well proven anti-oxidant activity and can protect human chondrocytes from 
apoptosis and dysfunction by inhibiting AP-1/NF-kB signalling and consequent production of 
IL-1β and activation of MMP-3.
172
 The inhibitory effect on NF-kB signaling by curcumin 
may be, at least in part, due to the activation of Nrf2. Curcumin stimulates HO-1 gene activity 
by promoting inactivation of the Nrf2–Keap1 complex, leading to increased Nrf2 binding to 
the resident HO-1 AREs.
173 
Calycosin, a compound derived from the Chinese medicinal herb 
Radix Astragali, has similar effect as it activates HO-1 and Nrf2 in synovial fibroblasts from 
arthritic patients, and inhibits pro-inflammatory factors.
174
 The widely applied antioxidant 
ascorbic acid (AA) was able to reduce apoptosis and loss of viability, and markedly decreased 
H2O2-mediated senescence of chondrocytes. AA stimulated the expression of collagens and 
proteoglycans, as well as inhibited chondrocyte differentiation under oxidative stress through 
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decreasing the activity of Nrf2, NF-kB, AP1 and MMP-3.
153
 Sesame oil treatment for seven 
days significantly decreased OA-associated joint pain, by decreasing IL-6, increasing CS 
activity and myosin heavy chain IIa mRNA expression. Sesame oil decreased muscular lipid 
peroxidation, activated Nrf2, inhibited ROS and increased glutathione production and 
glutathione peroxidase activity.
139
 Protandim
®
 (plant-derived science-based formulation) and 
6-gingerol preserved chondrocytes viability and mitochondrial metabolism through Nrf2 
upregulation and subsequent reduction of IL-1β and MMP-13.
3
 Wogonin, a naturally 
occurring flavonoid, revealed potent anti-inflammatory and chondroprotective effects through 
the activation of ROS/ERK/Nrf2 signaling pathways in human osteoarthritis chondrocytes. 
This molecule completely suppressed the expression and production of inflammatory 
mediators (IL-6, COX-2, PGE2, iNOS and NO), as well as, matrix degrading proteases 
including MMP-13, MMP-3, MMP-9.
175
 
It is noteworthy that the dose responses of exposures to some of the phytochemicals 
discussed above are often non-linear J-shaped or inverted U-shaped.
176,177
 Dose responses of 
this type are known as hormetic dose responses, and are characterized by a low-dose 
stimulation and a high-dose inhibition.
178
 The initial event is mild stress, which subsequently 
engages cellular stress response mechanisms, including those regulated by Nrf2. The 
transcriptional upregulation of Nrf2-dependent as well as other inducible cytoprotective 
proteins (also known as vitagenes) allows adaptation and survival, and enhanced resistance to 
subsequent challenges, such as those caused by oxidative stress and chronic inflammation.
179
  
In addition, natural and synthetic compounds can modulate NLRP3 inflammasome 
activation via Nrf2. For example treatment of mice with lupus nephritis with 
epigallocatechin-3-gallate (EGCG) or with citral (3,7-dimethyl-2,6-octadienal; a major 
active compound in a Chinese herbal medicine Litsea cubeba) attenuates NLRP3 
inflammasome activation via Nrf2 signaling.
180,181
 By a similar mechanism, mangiferin (2-
C-β-d-gluco-pyranosyl-1,3,6,7-tetrahydroxyxanthone) protects mice with sepsis-induced 
acute kidney-injury,
182
 biochanin inhibits acute liver injury,
183
 and antroquinonol (active 
compound from Antrodia camphorata) mitigates IgA nephropathy in mice.
184
 
Several studies have pointed to the cytoprotective potential of Nrf2 against 
glucocorticoid-induced apoptosis of osteoblastic cells. Dexamethasone-induced ROS 
production is suppressed by Nrf2 activation and antioxidant enzymes expression by indole-
3-carbinol
185
 and by sulforaphane (a naturally occurring isothiocyanate)
186
 and icariside 
II.
187
 Notably, sulforaphane, one of the most potent naturally occurring Nrf2 activators 
known to date, has been shown to suppress pro-inflammatory resposnes and protect cultured 
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human chondrocytes against various pro-inflammatory and pro-apoptotic stimuli, including 
shear stress.
188,189
 When included in the diet, sulforaphane (3 µM/day) decreased the arthritis 
score in a mouse model of osteoarthritis.
154
 The cytotoxic effect of methylglyoxal on 
osteoblastic cells was reversed by glabridin by Nrf2 activation, increases in HO-1 and 
glyoxalase I, and normalization of mitochondrial function.
190
 Icariside II, synthetic SC79 
and OSU53 can also prevent dexamethasone-induced apoptosis of osteoblasts via Akt 
activation downstream of Nrf2.
187,191,192
 All of these compounds may have potential to limit 
osteoblast cell death, which could lead to osteoporosis or osteonecrosis. 
 
Conclusions and future directions 
ROS signaling may play a dual role in OA. At low physiological levels, ROS can be 
important for cartilage and bone integrity by sustaining nuclear programing during 
chondrogenesis, osteoclasts and osteoblasts differentiation probably via Nrf2-sequestration 
mechanisms. Aging, mechanical load and inflammation can increase ROS production and can 
trigger oxidative stress with mitochondrial dysfunction, disturbances in cell signaling and 
alterations in epigenetic control of gene expression. Consequently, high level of ROS 
signaling and altered Nrf2 activity can increase chondrocyte apoptosis with cartilage 
degradation, induce chondrocyte hypertrophy and dysfunction in subchondral bone. 
Decreased Nrf2 activity may be a result of a failure in its homeostatic post-translational 
regulation and/or altered epigenetic and transcriptional regulatory mechanisms. Experimental 
evidence suggests that the role of Nrf2 in bone integrity is complex. Low Nrf2 activity may 
sustain bone resorption favoring osteoclastogenesis at early stages of OA, whereas high Nrf2 
activity may enhance osteoblastogenesis in advanced disease stage, inducing extensive bone 
remodeling.  Therapeutic approaches to increase Nrf2 activity by pharmacological agents may 
counteract oxidative stress and inflammation in OA thus effectively limiting cartilage 
degradation and bone resorption, whereas overall restoration of homeostatic Nrf2 activity may 
be required to normalize imbalanced bone resorption and remodeling. 
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Figure Legends 
 
Figure 1. Domain structure of Nrf2. The relative positions of the Nrf2 ECH homology 
(Neh) 1–7 domains are shown. The numbering of amino acids is based on the human protein. 
The DLG and ETGE motifs in the Neh2 domain that bind Keap1, and the DSGIS and 
DSAPGS motifs in the Neh6 domain that bind β-TrCP, are indicated. The Neh4 and Neh5 
domains form the transactivation domain of Nrf2 that recruits CREB-binding protein (CBP). 
The retinoid X receptor α (RXRα) binds to the Neh7 domain of Nrf2, leading to repression of 
the transcription factor. Neh1 mediates binding to DNA and to the heterodimeric partner of 
Nrf2, a small Maf transcription factor. Neh3 recruits the chromo-ATPase/helicase DNA-
binding protein 6 (CHD6). 
 
Figure 2. Regulation of Nrf2 by ubiquitination and proteasomal degradation. Three 
known ubiquitin ligase systems mediate the ubiquitination of Nrf2: (i) Kelch-like ECH 
associated protein 1 (Keap1), a substrate adaptor protein for Cullin-3 (Cul3)-Rbx1/Roc1 
ubiquitin ligase (i.e. CRL
Keap1
), which binds through its Kelch domains to the DLG and ETGE 
motifs in the Neh2 domain of Nrf2. For substrate adaptor activity, the cysteine sensors of 
Keap1 are in reduced state; (ii) β-transducin repeat-containing protein (β-TrCP), a substrate 
adaptor for the Skp1-Cul1-Rbx1/Roc1 E3 ligase complex (i.e. SCF
β-TrCP
). Recognition by β-
TrCP requires formation of a DSGIS motif-containing phosphodegron in the Neh6 domain of 
Nrf2 by glycogen synthase kinase 3 (GSK3), which in turn requires phosphorylation of Nrf2 
by a priming kinase; and (iii) the E3 ubiquitin ligase Hrd1/synoviolin, an endoplasmic 
reticulum (ER) protein. Degradation by Hrd1 has been shown to occur during ER stress. 
 
Figure 3. Role of ROS signaling in OA pathology. The low level of ROS can sustain 
cartilage and bone integrity as ROS regulate nuclear programing during osteoclasts and 
osteoblasts differentiation. At high level ROS can trigger oxidative stress with mitochondrial 
dysfunction and a failure in cells signaling and epigenetic regulation of gene expression. 
Oxidative stress causes inflammation, chondrocyte apoptosis with cartilage degradation and 
dysfunction in subchondral bone with imbalanced bone resorption and remodeling.     
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Figure 4. Role of Nrf2 in OA. Bone resorption at early stage of OA is due to a favorable 
osteoclastogenesis via low Nrf2/Keap ratio (as shown by Nrf2 deficiency). In advanced 
stage of OA, intensive bone remodeling triggered as a compensatory mechanism to bone 
resorption is more likely related with enhanced osteoblastogenesis via high Nrf2/Keap ratio 
(as shown by Nrf2 overexpression). The therapy approaches in OA may involve a 
normalization of bone/resorption and remodeling via interference with Nrf2 expression and 
ROS signaling. 
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Figure 1. Domain structure of Nrf2. The relative positions of the Nrf2 ECH homology (Neh) 1–7 domains are 
shown. The numbering of amino acids is based on the human protein. The DLG and ETGE motifs in the Neh2 
domain that bind Keap1, and the DSGIS and DSAPGS motifs in the Neh6 domain that bind β-TrCP, are 
indicated. The Neh4 and Neh5 domains form the transactivation domain of Nrf2 that recruits CREB-binding 
protein (CBP). The retinoid X receptor α (RXRα) binds to the Neh7 domain of Nrf2, leading to repression of 
the transcription factor. Neh1 mediates binding to DNA and to the heterodimeric partner of Nrf2, a small Maf 
transcription factor. Neh3 recruits the chromo-ATPase/helicase DNA-binding protein 6 (CHD6).  
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Figure 2. Regulation of Nrf2 by ubiquitination and proteasomal degradation. Three known ubiquitin ligase 
systems mediate the ubiquitination of Nrf2: (i) Kelch-like ECH associated protein 1 (Keap1), a substrate 
adaptor protein for Cullin-3 (Cul3)-Rbx1/Roc1 ubiquitin ligase (i.e. CRLKeap1), which binds through its Kelch 
domains to the DLG and ETGE motifs in the Neh2 domain of Nrf2. For substrate adaptor activity, the 
cysteine sensors of Keap1 are in reduced state; (ii) β-transducin repeat-containing protein (β-TrCP), a 
substrate adaptor for the Skp1-Cul1-Rbx1/Roc1 E3 ligase complex (i.e. SCFβ-TrCP). Recognition by β-TrCP 
requires formation of a DSGIS motif-containing phosphodegron in the Neh6 domain of Nrf2 by glycogen 
synthase kinase 3 (GSK3), which in turn requires phosphorylation of Nrf2 by a priming kinase; and (iii) the 
E3 ubiquitin ligase Hrd1/synoviolin, an endoplasmic reticulum (ER) protein. Degradation by Hrd1 has been 
shown to occur during ER stress.  
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Figure 3. Role of ROS signaling in OA pathology. The low level of ROS can sustain cartilage and bone 
integrity as ROS regulate nuclear programing during osteoclasts and osteoblasts differentiation. At high level 
ROS can trigger oxidative stress with mitochondrial dysfunction and a failure in cells signaling and epigenetic 
regulation of gene expression. Oxidative stress causes inflammation, chondrocyte apoptosis with cartilage 
degradation and dysfunction in subchondral bone with imbalanced bone resorption and remodeling.  
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Figure 4. Role of Nrf2 in OA. Bone resorption at early stage of OA is due to a favorable osteoclastogenesis 
via low Nrf2/Keap ratio (as shown by Nrf2 deficiency). In advanced stage of OA, intensive bone remodeling 
triggered as a compensatory mechanism to bone resorption is more likely related with enhanced 
osteoblastogenesis via high Nrf2/Keap ratio (as shown by Nrf2 overexpression). The therapy approaches in 
OA may involve a normalization of bone/resorption and remodeling via interference with Nrf2 expression and 
ROS signaling.  
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